In July 2018, the U.S. Federal Drug Administration officially approved the first new medicine for relapsing malaria in more than 60 years.
The development of the drug, tafenoquine, was funded by the Bill and Melinda Gates Foundation. Foundation CEO Dr. Sue Desmond-Hellmann says that approval of the drug “is a major milestone along the road to ending the scourge of malaria for good.”
While this event is notable in itself, tafenoquine (also known by the name Krintafel) is quite impressive. The drug is a single-dose treatment that fights the most prevalent human malaria parasite in the world, Plasmodium vivax.